Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for the Acute Treatment of Migraine (ECLIPSE)
NCT06241313Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of atogepant in migraine (4 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants Achieving Pain Freedom at 2 hours. Started Mar 2024; status: completed.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06241313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241313.